NEULANDLAB Overzicht aandelen
Neuland Laboratories Limited produceert en verkoopt actieve farmaceutische ingrediënten (API's) in India, Europa, de Verenigde Staten en internationaal. Meer informatie
Sneeuwvlok Score | |
---|---|
Waardering | 1/6 |
Toekomstige groei | 5/6 |
Prestaties in het verleden | 4/6 |
Financiële gezondheid | 6/6 |
Dividenden | 0/6 |
Neuland Laboratories Limited Concurrenten
Prijsgeschiedenis en prestaties
Historische aandelenkoersen | |
---|---|
Huidige aandelenkoers | ₹16,068.90 |
52 Week Hoogtepunt | ₹16,560.75 |
52 Week Laag | ₹4,926.05 |
Bèta | 0.98 |
11 maand verandering | 15.18% |
3 maanden verandering | 29.54% |
1 Jaar Verandering | 210.71% |
33 jaar verandering | 813.32% |
5 jaar verandering | 3,519.94% |
Verandering sinds IPO | 16,814.63% |
Recent nieuws en updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Rendement voor aandeelhouders
NEULANDLAB | IN Pharmaceuticals | IN Markt | |
---|---|---|---|
7D | 7.9% | 1.1% | 2.0% |
1Y | 210.7% | 43.3% | 28.6% |
Rendement versus industrie: NEULANDLAB overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 43.3 % opleverde.
Rendement versus markt: NEULANDLAB overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 28.6 %.
Prijsvolatiliteit
NEULANDLAB volatility | |
---|---|
NEULANDLAB Average Weekly Movement | 9.4% |
Pharmaceuticals Industry Average Movement | 6.1% |
Market Average Movement | 6.1% |
10% most volatile stocks in IN Market | 9.1% |
10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: De aandelenkoers van NEULANDLAB is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van NEULANDLAB is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Indian.
Over het bedrijf
Opgericht | Werknemers | CEO | Website |
---|---|---|---|
1984 | 1,643 | Davuluri Rao | www.neulandlabs.com |
Neuland Laboratories Limited produceert en verkoopt actieve farmaceutische ingrediënten (API's) in India, Europa, de Verenigde Staten en internationaal. Het bedrijf biedt ook aangepaste productieoplossingen en diensten op het gebied van peptidensynthese. Neuland Laboratories Limited werd opgericht in 1984 en het hoofdkantoor is gevestigd in Hyderabad, India.
Neuland Laboratories Limited Samenvatting
NEULANDLAB fundamentele statistieken | |
---|---|
Marktkapitalisatie | ₹206.36b |
Inkomsten(TTM) | ₹2.80b |
Inkomsten(TTM) | ₹15.28b |
73.8x
Koers/Winstverhouding13.5x
P/S-verhoudingIs NEULANDLAB overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
NEULANDLAB resultatenrekening (TTM) | |
---|---|
Inkomsten | ₹15.28b |
Kosten van inkomsten | ₹7.31b |
Brutowinst | ₹7.97b |
Overige uitgaven | ₹5.17b |
Inkomsten | ₹2.80b |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) | 217.98 |
Brutomarge | 52.14% |
Nettowinstmarge | 18.30% |
Schuld/Eigen Vermogen Verhouding | 6.7% |
Hoe presteerde NEULANDLAB op de lange termijn?
Bekijk historische prestaties en vergelijking